Deadpool blend
Deadpool blend (BPC-157 + TB-500 + KPV)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Deadpool stack, Copper-free healing blend, BPC-157 TB-500 KPV blend
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Deadpool is three healing peptides in one vial. It is KLOW with the copper taken out. The usual vial is 10 mg each of BPC-157, TB-500 and KPV. Here is the catch with this one. Sellers use the name Deadpool for at least three different mixes. One of them is KLOW with a new name. So the word on the label does not tell you what is inside.
What people take it for
- Healing a tendon or a joint faster.
- Calming the gut.
- Less swelling all over.
- One shot instead of three.
What the trials actually showed
No one has tested these three together. Not in people. Not in mice. What exists is a thin file on each part. BPC-157 was reviewed by the FDA in 2026. They found five human studies with fewer than 110 people in total. Two were meeting abstracts. None ran longer than two weeks. None used a shot under the skin. A 2025 review of BPC-157 pulled in 36 studies. Thirty five were in animals. The one human study looked back at 12 knee patients, and 7 of them said the pain stayed away past six months. TB-500 has no human study at all. A drug testing lab ran the product through a machine and found a 7 amino acid piece of a 43 amino acid protein. KPV has no human data of any kind. Now the math. Mix the 30 mg with 3 mL of water. Every unit mark on the syringe carries about 33 micrograms of each of the three. Draw 7.5 units and you get 250 micrograms of each.
What people report
Reports, not trial results
The good
- Less tendon and joint pain in the first few weeks. Same thing people say about BPC-157 on its own.
- Gut symptoms settling down, which people credit to the KPV.
- Less stinging at the shot site than the copper blends.
The bad
- No effect at all is a common report.
- Not knowing what you bought. The same name covers several mixes.
- You cannot turn one part down. One plunger moves all three.
- The three parts do not share a schedule. BPC-157 is gone in half an hour and people shoot it daily. The TB-500 piece gets run once a week. A blend cannot do both.
Where these come from: Peptide forums, vendor listings and price comparison sites. These are people talking, not trial data. The FDA count and the 2025 review are real studies and are listed on this page.
My bottom line
Nobody has tested this mix, and the name does not even tell you which mix you bought. If you want to know what one of these peptides does for you, buy one of them.
An opinion, not a finding. I am a coach, not a doctor.
Overview
A three-peptide repair vial, most often 10 mg each of BPC-157, TB-500 and KPV, sold as KLOW without the copper. No study has tested the three together in any species. The name is the real hazard: different vendors sell at least three different formulas under it, including one that is KLOW relabelled and one built on a different peptide entirely, so the word on the label does not identify the contents.
Deadpool is a marketing name, not a formula. Search the vendors and you find the same word on a 30 mg vial holding 10 mg each of BPC-157, TB-500 and KPV, on a 20 mg vial split 10 mg TB-500, 5 mg BPC-157 and 5 mg KPV, on a copper-loaded vial that is KLOW under another name, and on a three-peptide vial built around cartalax rather than KPV. That is the first fact about this product and it is not a small one. Two people comparing notes on Deadpool may be describing chemically different things.
This page takes the copper-free triple as the reference formula, because that is the version the name most consistently attaches to. Take the even split: 10 mg each, 30 mg of powder. Put 3 mL of bacteriostatic water in and the vial holds 10 mg/mL of total powder and 3.33 mg/mL of each component. One unit mark on a 100 unit insulin syringe is 0.01 mL, so every unit delivers about 33 micrograms of each of the three. Draw to 250 micrograms of BPC-157, which is the amount people run when they use that peptide alone, and you are at roughly 7.5 units. Those same 7.5 units deliver 250 micrograms of TB-500 and 250 micrograms of KPV.
That last sentence is the problem in one line. When people run TB-500 on its own they describe a loading phase in milligrams, not micrograms, then a weekly maintenance dose. An even split forces TB-500 down to a BPC-157 amount, or forces BPC-157 up to a TB-500 amount, and one plunger decides which. There is no schedule that is right for both either. The BPC-157 systematic review puts its half-life at under 30 minutes, which is why people inject it once or twice a day; the actin-binding fragment sold as TB-500 is dosed weekly by the same community. A daily schedule stacks the fragment and a weekly schedule wastes most of the BPC-157.
Strip out the copper and you also strip out the one component with any human data at all, however thin and however topical. What is left is a preclinical animal literature, a seven amino acid fragment whose parent protein is a different molecule, and a tripeptide with no registered human study of any kind.
Mechanism of action
Assumed additive, and assumed is doing the work. BPC-157 acts through the angiogenic and tissue repair pathways described on its own page, almost entirely in rodents. The Ac-LKKTETQ fragment sold as TB-500 binds actin. KPV is the C-terminal tripeptide of alpha-MSH and suppresses NF-kB and MAP kinase signalling in intestinal epithelial and immune cells. No paper describes what the three do in one solution, whether their effects add or overlap, or how three peptides with different stability profiles behave in a shared vial over the weeks it sits in a fridge.
Human evidence
None for the combination. The per-component human record is three separate thin files, and one of the three is empty.
- The blend: no published study in any species, and no registered trial of the three together.
- BPC-157: FDA counted five human studies totalling fewer than 110 subjects, two of them meeting abstracts, none longer than two weeks and none by subcutaneous injection. A 2025 systematic review found 35 of 36 included studies were preclinical, the one clinical study being a retrospective series of 12 knee patients.
- TB-500: no human study by any route. The product was characterised in a doping laboratory as a seven amino acid fragment of thymosin beta 4.
- KPV: no human data of any kind. ClinicalTrials.gov returns no registered study. The record is mouse colitis, cell culture, and a review that lists melanocortin peptides as future candidates.
What this does not tell you: Nothing in these three literatures speaks to what happens when they arrive together at a ratio a vendor chose, on a schedule that suits none of them, in a person rather than a rat. No combined adverse event profile exists.
What it has been measured to do
Measured in animals or cells, not yet in people
Real results that answer a different question from a trial. Where a human trial is missing on a compound nobody can patent, the reason is usually that no sponsor would ever recover the cost of running one. The record on this one is set out below.
- Losing weight1 preclinical study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with Deadpool blend, what they expect, and what goes wrong. The full account, including the negative reports, is below.
33 of the 36 indexed goals have no study of any kind behind Deadpool blend
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Deadpool blend and one of these did not come from a study cited here.
Reading the research record
The name is the part worth carrying away. Vendor listings under Deadpool differ in component count, in component identity and in ratio, and no standards body governs any of it. Anyone comparing experiences with another buyer is probably not comparing the same product, which quietly makes every anecdote about it unreadable.
The second thing is what the copper-free framing hides. Removing GHK-Cu removes a real concern, because a copper-loaded vial is a copper load nobody is measuring. It also removes the only ingredient in the KLOW family that has ever been given to a human being in a controlled study, and that study was a cream that failed its objective endpoints. Copper-free is a genuinely safer vial and an even thinner one.
The evidence, charted
Fig. 1a · evidence scale
0people have taken this in any study cited here
0 participants · 0 human studies
What this page cites instead is 1 animal study, 1 in vitro study and 3 reviews. None of it involved giving the compound to a person.
Counted from the citation list on this page. A figure is drawn here only when a human study is cited; an empty one is the finding, not a gap in the page.
Fig. 1b · evidence mix
None of the 5 citations here are human work.
- Animal · given to animals120%
- In vitro · cells, tissue or a dish120%
- Review · summarises other work360%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2008 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- A mixture. BPC-157 is about 1,419 Da, the Ac-LKKTETQ fragment about 889 Da, and KPV about 342 Da.
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. The components clear at very different rates and no pharmacokinetic study of the mixture exists.
No amino acid sequence is on file for Deadpool blend, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
33.3%of a 30 mg Deadpool blend vial is BPC-157
Label mass from a standard vial, not a dose, and not an assay. The ratio is fixed by the seller, so a draw that hits the amount you want of one component sets the amount of every other component with it. No study has tested this combination in any species.
Key studies & citations
- Review2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
544 articles screened, 36 included, of which 35 were preclinical and one was clinical. That single clinical study was a retrospective series in which 7 of 12 patients reported relief beyond six months after intra-articular BPC-157 for unspecified chronic knee pain. The review puts the half-life at under 30 minutes.
HSS Journal - Review2026
FDA briefing document on BPC-157 for the July 2026 PCAC meeting
FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.
FDA - In vitro2012
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
A doping control laboratory ran the TB-500 product through high performance liquid chromatography and high resolution mass spectrometry and identified the contents as Ac-LKKTETQ, the acetylated 17 to 23 fragment of thymosin beta 4. Seven amino acids, not the 43 amino acid protein the marketing names.
Drug Testing and Analysis - Animal2008
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
In two mouse colitis models KPV produced earlier recovery, greater body-weight regain, fewer inflammatory infiltrates and lower myeloperoxidase activity in colon tissue. Mice, KPV given alone, nothing here about a blend or about people.
Inflammatory Bowel Diseases - Review2019
Are melanocortin peptides future therapeutics for cutaneous wound healing?
A dermatology review describing KPV as a truncated alpha-MSH peptide that keeps the anti-inflammatory activity without the pigment-inducing activity, and proposing peptides of this class as future candidates for cutaneous wounds. The experimental approaches it surveys are in silico, in vitro, ex vivo and animal.
Experimental Dermatology
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Reduced tendon and joint pain in the first few weeks, described the same way people describe BPC-157 alone.
- Gut symptoms settling, credited to the KPV.
- Less injection site irritation than the copper blends, which people attribute to the absence of the acidic copper solution.
- Confusion about what was actually bought, because the same name covers several formulas.
- No effect at all, which is common and rarely reposted.
Sources: Peptide forums including r/peptides, vendor product pages and price-comparison listings. Uncontrolled self-reports from people usually running other compounds at the same time. Recorded as reports, not evidence.
Frequently asked questions
Has anyone studied the Deadpool blend?
No. There is no published study of BPC-157 with TB-500 and KPV together, in animals or people, and no registered trial of the combination.
What is actually in the vial?
It depends on the vendor, which is the single most important thing to know about this product. The most common version is 10 mg each of BPC-157, TB-500 and KPV in a 30 mg vial. Others sell 10 mg TB-500 with 5 mg each of BPC-157 and KPV, some sell a copper version that is KLOW under a different name, and at least one uses a different third peptide. Read the milligram breakdown, not the name.
How much do I get per unit on the syringe?
On the even 10 plus 10 plus 10 vial reconstituted with 3 mL, each unit mark carries about 33 micrograms of each of the three peptides. A 7.5 unit draw is about 250 micrograms of each.
Is it better than the copper blends?
It is a different trade. You lose the copper load, which nobody has measured in an injecting human. You also lose the only component in that family with any controlled human data, and that data was a cream that failed its blinded endpoints. Neither version has been tested as a combination.
Why can I not dose the TB-500 separately?
Because one plunger moves all three. People running the fragment alone use milligram loading doses and weekly maintenance. People running BPC-157 alone use microgram doses once or twice a day. An even blend cannot do both, and the vendor already chose which one you get.